-
Express aims to functionally cure HIV infection, CRISPR gene editing therapy is about to start phase 1 clinical trials
Time of Update: 2021-10-01
EBT-101 is a CRISPR-based candidate therapy designed to functionally cure chronic type 1 human immunodeficiency virus (HIV-1) infection .
"Reference: [1] Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV.
Retrieved September 15, 2021, from https:// -release/2021/09/15/2297456/0/en/Excision-Receives-FDA-Clearance-of-IND-for-Phase-1-2-Trial-of-EBT-101-CRISPR-Based-Therapeutic-for -Treatment-of-HIV.
-
To treat HIV, CRISPR gene editing therapy targeting multiple sites enters clinical trials
Time of Update: 2021-10-01
EBT-101 is a therapeutic drug based on CRISPR gene editing in vivo, designed to remove the proviral DNA that HIV integrates into the human cell genome .
-
CRISPR gene editing therapy aimed at functional cure of HIV infection is about to start phase 1 clinical trial
Time of Update: 2021-09-18
EBT-101 is a CRISPR-based candidate therapy designed to functionally cure chronic type 1 human immunodeficiency virus (HIV-1) infection .
Reference materials:[1] Excision Receives FDA Clearance of IND for Phase 1/2 Trial of EBT-101 CRISPR-Based Therapeutic for Treatment of HIV.
Retrieved September 15, 2021, from https:// /09/15/2297456/0/en/Excision-Receives-FDA-Clearance-of-IND-for-Phase-1-2-Trial-of-EBT-101-CRISPR-Based-Therapeutic-for-Treatment-of -HIV.
-
CRISPR gene editing to knock out PD-1 improved ready-to-use CAR-T therapy enters clinical trials
Time of Update: 2021-08-03
Caribou was co-founded by Nobel Prize winner Professor Jennifer Doudna, aiming to develop next-generation genome editing cell therapy using RNA-DNA hybrid sequence-mediated CRISPR gene editing system (chRDNA) .
-
Boya submitted the country's first CRISPR gene editing therapy clinical trial application
Time of Update: 2020-11-11
On October 27th, Boya announced that the Drug Review Center of the State Drug Administration had accepted its clinical trial application for a gene-editing therapy product for transfusion-dependent β thalassemia, ET-01, or CRISPR/Cas9 gene-modified self-made CD34 plus hematocyte injection of BCL11A red line enhancers.
-
CRISPR Gene Editing Therapy Human Clinical Trials Release Positive Data
Time of Update: 2020-06-01
Both beta thalassemia and sickle cell anemia are blood disorders caused by mutations in genes that encode hemoglobin Severe patients often need to be treated with regular red blood cell input, which n
-
CRISPR gene editing therapy human clinical trials release positive data
Time of Update: 2019-11-20
CRISPR therapeutics and vertex pharmaceuticals announced yesterday that CRISPR / cas9 gene editing therapy ctx001 has yielded positive interim data in ongoing phase 1 / 2 clinical trials One patient w